Price T Rowe Associates Inc I Mab Transaction History

Price T Rowe Associates Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $36.7 Million - $81.9 Million	-4,442,356 Reduced 82.34%	952,801 $10.8 Million
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $24.5 Million - $91.7 Million	-1,953,615 Reduced 26.58%	5,395,157 $87.6 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $112 Million - $184 Million	2,463,847 Added 50.44%	7,348,772 $348 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $231 Million - $341 Million	4,039,773 Added 477.99%	4,884,925 $354 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $7.48 Million - $13.1 Million	156,332 Added 22.7%	845,152 $71 Million

Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $30.6 Million - $44.1 Million	688,820 New	688,820 $33.4 Million

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.